|
Last Updated: Nov 17th, 2006 - 22:35:04 |
Latest Research
:
Cancer
:
Rectal Cancer
TNFerade(TM) to Continue in Phase II Trial
GenVec, Inc. (Nasdaq:GNVC) announced today that the U.S. Food and Drug Administration (FDA) informed the company that it may resume its Phase II clinical trial of TNFerade(TM) in rectal cancer. This trial will be conducted in collaboration with the Surgery Branch of the National Cancer Institute to evaluate the use of TNFerade in combination with chemoradiation for rectal cancer to improve complete response rates, surgical outcomes and survival.
May 25, 2005, 20:52
Latest Research
:
Cancer
:
Rectal Cancer
Radiotherapy for Prostate Cancer Doubles risk for Rectal Cancer
A University of Minnesota Cancer Center study indicates that men who undergo radiation therapy for prostate cancer have nearly double the risk of developing rectal cancer when compared to men who opt to have surgery to treat prostate cancer.
Apr 3, 2005, 11:44
|
